DOCSLIB.ORG

Commercial Biotechnology: an International Analysis (Part 3 Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Commercial Biotechnology: an International Analysis (Part 3 Of Chapter 1 Summary . Contents Page Introduction . 3 Definitions . 3 The Technologies . 4 Industrial Development. s Findings . 6 Industrial Applications of Biotechnology . 6 The U.S. Competitive Position . 7 Analysis of International Competitiveness in Biotechnology . 8 The Importance of Established and New Firms in the Commercialization of Biotechnology 11 Factors Potentially Important to International Competitiveness in Biotechnology . 12 Other Influences on Competitiveness in Biotechnology . 20 Conclusion . 21 Issues and Options . .. .. .. .. ... ... ...~... 22 Figures Figure No). Page l.Major Events in the Commercialization of Biotechnology . 4 2. The Relative Importance of Factors Affecting the Commercialization of Biotechnology . 10 Chapter 1 Summary Introduction In the past 10 years, dramatic new develop- identified new biotechnology as a promising area ments in the ability to select and manipulate ge- for economic growth and have therefore invested netic material have sparked unprecedented in- quite heavily in R&D in this field, Congressional terest in the industrial uses of living organisms. policy options for improving U.S. competitiveness Following the first successful directed insertion in new biotechnology are identified in this report. of foreign DNA in a host microorganism in 1973, scientific researchers in the United States and other countries began to recognize the potential Definitions for directing the cellular machinery to develop new and improved products and processes in a Biotechnology, broadly defined, includes any wide diversity of industrial sectors. Potential in- technique that uses living organisms (or parts of dustrial applications of those novel genetic tech- organisms) to make or modify products, to im- niques include the production of new drugs, food, prove plants or animals, or to develop microorga- and chemicals, the degradation of toxic wastes, nisms for specific uses. Biological processes and and the improvement of agricultural products. organisms have been used with great success Thus, these new techniques could have a major throughout history and have become increasing- economic impact on industries throughout the ly sophisticated over the years. Since the dawn world. of civilization, people have deliberately selected organisms that improved agriculture, animal hus- Beginning around 1976, many small entrepre- bandry, baking, and brewing. More recently, a neurial firms were formed in the United States better understanding of genetics has led to more specifically to build on the growing body of fun- effective applications of traditional genetics in damental knowledge in molecular biology and to such areas as antibiotic and chemical production. exploit it to a profitable end. Furthermore, large established American, Japanese, and European This report focuses on the industrial use of companies in a spectrum of industrial sectors ex- recombinant DNA (rDNA, cell fusion~ and panded their research and development (R&D) novel bioprocessing techniques To differen- programs to include the new genetic techniques. tiate between biotechnology using these novel In the United States, private sector investments techniques and the more traditional forms of bio- to commercialize these new techniques exceeded technology, this report uses the terms ‘(new bio- $1 billion in 1983. technology” and “old biotechnology)” respective- ly. Thus, for example, traditional wine produc- This report assesses the competitive position of tion is old biotechnology, but the use of yeast the United States with respect to Japan and four modified with rDNA techniques to produce wine European countries-the Federal Republic of Ger- with a higher alcohol content is new biotech- many, the United Kingdom, Switzerland, and nology. Where no specific distinction is made, the France—believed to be the major competitors in term biotechnology alone henceforth refers to the commercial development of “new biotechnol- new biotechnology. ogy,” as defined below. Although the United States is currently the world leader in both Biotechnology is the most recent phase in a his- basic science and commercial development of torical continuum of the use of biological orga- new biotechnology, continuation of the initial nisms for practical purposes. Furthermore, devel- preeminence of American companies in the opments arising from existing technologies are commercialization of new biotechnology is providing a base from which other technologies not assured. Japan and other countries have will emerge, and new technologies can make even 3 4 . Commercial Biotechnology: An International Analysis the most potentially useful current technology ob- direct which genes are used by cells permits more solete in a short time. Of necessity, this assess- control over the production of biological mole- ment describes the development of biotechnology cules than ever before. Recombinant DNA tech- at a particular point in time, but it is important nology can be used in a wide range of industrial to emphasize that dynamic and progressive sectors to develop micro-organisms that produce change has characterized biotechnology for the new products, existing products more efficient- last decade. Figure 1 shows some prominent ly, or large quantities of otherwise scarce prod- events that illustrate the rapid progress made in ucts. This technology can also be used to develop the development of biotechnology over the last organisms that themselves are useful, such as decade. This pace is likely to continue into the microorganisms that degrade toxic wastes or new 21st century. strains of agriculturally important plants. The technologies Cell fusion, the artificial joining of cells, com- bines the desirable characteristics of different The novel techniques used in biotechnolo types of cells into one cell. This technique has gy are extremely powerful because they allow been used recently to incorporate in one cell the a large amount of control over biological sys- traits for immortality and rapid proliferation from tems Recombinant DNA technology, one of the certain cancer cells and the ability to produce new techniques, allows direct manipulation of the useful antibodies from specialized cells of the im- genetic material of individual cells. The ability to mune system. The cell line resulting from such Figure 1 .—Major Events in the Commercialization of Biotechnology 1973 First gene cloned. 1974 First expression of a gene cloned from a different species in bacteria. Recombinant DNA (rDNA) experiments first discussed in a public forum (Gordon Conference). 7975 U.S. guidelines for rDNA research outlined (Asilomar Conference). First hybridoma created. T976 First firm to exploit rDNA technology founded in the United States (Genentech). Genetic Manipulation Advisory Group (U. K.) started in the United Kingdom. — 1980 Diamond v. Chakrabarty— U.S. Supreme Court rules that micro-organisms can be patented under existing law. Cohen/Boyer patent issued on the technique for the construction of rDNA. United Kingdom targets biotechnology (Spinks’ report). Federal Republic of Germany targets biotechnology (Leistungsplan). Initial public offering by Genentech sets Wall Street record for fastest price per share increase ($35 to $89 in 20 minutes). T981 First monoclinal antibody diagnostic kits approved for use in the United States. First automated gene synthesizer marketed. Japan targets biotechnology (Ministry of International Trade and Technology declares 1981 “The Year of Bio- technology”). France targets biotechnology (Pelissolo report). Hoescht/Massachusetts General Hospital agreement. Initial public offering by Cetus sets Wall Street record for the largest amount of money raised in an initial public offering ($1 15 million). Industrial Biotechnology Association founded. DuPont commits $120 million for life sciences R&D. Over 80 NBFs had been formed bv the end of the vear. 1982 First rDNA animal vaccine (for colibacillosis) approved for use in Europe. First rDNA pharmaceutical product (human insulin) approved for use in the United States and the United Kingdom. First R&D limited partnership formed for the funding of clinical trials. 383 First plant gene expressed in a plant of a different species. $500 million raised in U.S. public markets by NBFs. SOURCE: Office of Technology Assessment Ch. l—Summary ● 5 a fusion, known as a hybridoma, produces large chemical one. As discussed in this report, indus- quantities of monoclinal antibodies (MAbs), so trial applications of biotechnology will be called because they are produced by the progeny, found in several industrial sectors, including or clones, of a single hybridoma cell. MAbs can pharmaceuticals, animal and plant agricul- potentially be used for many purposes, including ture, specialty chemicals and food additives, the diagnosis and treatment of disease and the environmental areas, commodity chemicals purification of proteins. and energy production, and bioelectronics. The commercial success of specific industrial The industrial sector in which the earliest ap- applications of rDNA and cell fusion techniques plications of new biotechnology have occurred will hinge on advances in bioprocess engineering. is the pharmaceutical sector. Reasons for the Bioprocess technology, though not a novel genet- rapid diffusion of the new techniques into the ic technique, allows the adaptation of biological pharmaceutical sector include the following: methods of production to large-scale industrial ● Recombinant DNA and MAb technologies use. Most industrial
Load more

Recommended publications
  • Biosensors and Bioelectronics 142 (2019) 111530
    Biosensors and Bioelectronics 142 (2019) 111530 Contents lists available at ScienceDirect Biosensors and Bioelectronics journal homepage: www.elsevier.com/locate/bios Highly sensitive bioaffinity electrochemiluminescence sensors: Recent T advances and future directions ∗ Bahareh Babamiria,b, Delnia Baharia,b, Abdollah Salimia,b,c, a Department of Chemistry, University of Kurdistan, 66177-15175, Sanandaj, Iran b Research Center for Nanotechnology, University of Kurdistan, 66177-15175, Sanandaj, Iran c Department of Chemistry, University of Western Ontario, N6A 5B7, London, Ontario, Canada ARTICLE INFO ABSTRACT Keywords: Electrogenerated chemiluminescence (also called electrochemiluminescence and abbreviated ECL) has attracted Electrochemiluminescence much attention in various fields of analysis due to the potential remarkably high sensitivity, extremely wide Bioaffinity sensors dynamic range and excellent controllability. Electrochemiluminescence biosensor, by taking the advantage of Aptasensor the selectivity of the biological recognition elements and the high sensitivity of ECL technique was applied as a Immunoassays powerful analytical device for ultrasensitive detection of biomolecule. In this review, we summarize the latest Genosensor sensing applications of ECL bioanalysis in the field of bio affinity ECL sensors including aptasensors, im- Cytosensor Medical diagnostics munoassays and DNA analysis, cytosensor, molecularly imprinted sensors, ECL resonance energy transfer and Nanomaterials ratiometric biosensors and give future perspectives for new developments in ECL analytical technology. Furthermore, the results herein discussed would demonstrate that the use of nanomaterials with unique chemical and physical properties in the ECL biosensing systems is one of the most interesting research lines for the development of ultrasensitive electrochemiluminescence biosensors. In addition, ECL based sensing assays for clinical samples analysis and medical diagnostics and developing of immunosensors, aptasensors and cytosensor for this purpose is also highlighted.
    [Show full text]
  • Accomplishments in Nanotechnology
    U.S. Department of Commerce Carlos M. Gutierrez, Secretaiy Technology Administration Robert Cresanti, Under Secretaiy of Commerce for Technology National Institute ofStandards and Technolog}' William Jeffrey, Director Certain commercial entities, equipment, or materials may be identified in this document in order to describe an experimental procedure or concept adequately. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment used are necessarily the best available for the purpose. National Institute of Standards and Technology Special Publication 1052 Natl. Inst. Stand. Technol. Spec. Publ. 1052, 186 pages (August 2006) CODEN: NSPUE2 NIST Special Publication 1052 Accomplishments in Nanoteciinology Compiled and Edited by: Michael T. Postek, Assistant to the Director for Nanotechnology, Manufacturing Engineering Laboratory Joseph Kopanski, Program Office and David Wollman, Electronics and Electrical Engineering Laboratory U. S. Department of Commerce Technology Administration National Institute of Standards and Technology Gaithersburg, MD 20899 August 2006 National Institute of Standards and Teclinology • Technology Administration • U.S. Department of Commerce Acknowledgments Thanks go to the NIST technical staff for providing the information outlined on this report. Each of the investigators is identified with their contribution. Contact information can be obtained by going to: http ://www. nist.gov Acknowledged as well,
    [Show full text]
  • Bioelectronics Contents
    chapter 10 Bioelectronics Contents Introduction . 253 Biosensors. 253 Biochips. 254 Priorities for Future Research . 256 Chapter IO References . 256 Figure Figure No. Page 29.The Use of Proteins in Constructing Circuit . ..., . 255 — Chapter 10 Bioelectronics .—— .— Introduction --—----- ——— The potential for the use of proteins in elec- used for several years, but design problems have tronic dmices has received attention recently with limited their acceptance. Biotechnology is ex- the advent of recombinant DNA (rDNA) technol- pected to increase the variety, stability, and sen- ogy}’ and the potential for computer-aided design sitivity of these devices. Biochips (biologically of proteins (I ,2,3 5 ,6,7, 11, 13,14,15,19,2 1 ). Work based microchips) capable of logic and memory is focused in two areas: biosensors and biochips. are still only speculative, and their development Biosensors (biological}’ based sensors) have been is many years away. Biosensors -——-- –—- —— .——. A potential application of biotechnology is in the not only could obviate the need for enzymes but development of improved sensing devices. Be- also could substantially broaden the applications cause of their high specificity. for given sub- of biosensors. A longer term solution to the lack of stances, enzymes and monocIonal antibodies particular enzymes might be to have computers (hlAbs) are particularly suited for use as sensors. design enzymes with particular catalytic func- Sensors using these biological molecules have the tions. Finally, features of proteins that determine potential to be smaller and more sensitive than temperature stability could be incorporated into traditional sensors. the genes that code for important sensing en- zymes. Biosensors using enzymes have been used to detect the presence of various organic compounds A new approach to fabrication is yielding bio- for many years (12).
    [Show full text]
  • An Aptamer-Based Magnetic Flow Cytometer Using Matched Filtering
    Biosensors and Bioelectronics 169 (2020) 112362 Contents lists available at ScienceDirect Biosensors and Bioelectronics journal homepage: http://www.elsevier.com/locate/bios An aptamer-based magnetic flow cytometer using matched filtering Chih-Cheng Huang a, Partha Ray b, Matthew Chan c, Xiahan Zhou c, Drew A. Hall c,d,* a Materials Science and Engineering Program, University of California – San Diego, La Jolla, CA, 92093, USA b Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, UC San Diego Health, La Jolla, CA, 92093, USA c Department of Electrical and Computer Engineering, University of California – San Diego, La Jolla, CA, 92093, USA d Department of Bioengineering, University of California – San Diego, La Jolla, CA, 92093, USA ARTICLE INFO ABSTRACT Keywords: Facing unprecedented population-ageing, the management of noncommunicable diseases (NCDs) urgently needs Aptasensor a point-of-care (PoC) testing infrastructure. Magnetic flow cytometers are one such solution for rapid cancer Flow cytometry cellular detection in a PoC setting. In this work, we report a giant magnetoresistive spin-valve (GMR SV) Magnetic biosensor biosensor array with a multi-stripe sensor geometry and matched filteringto improve detection accuracy without Matched filtering compromising throughput. The carefully designed sensor geometry generates a characteristic signature when Pancreatic cancer Point-of-Care (PoC) testing cells labeled with magnetic nanoparticles (MNPs) pass by thus enabling multi-parametric measurement like optical flow cytometers (FCMs). Enumeration and multi-parametric information were successfully measured across two decades of throughput (37 — 2730 cells/min). 10-μm polymer microspheres were used as a bio­ mimetic model where MNPs and MNP-decorated polymer conjugates were flown over the GMR SV sensor array and detected with a signal-to-noise ratio (SNR) as low as 2.5 dB due to the processing gain afforded by the matched filtering.
    [Show full text]
  • Biotechnology Past, Present and Potential
    4i-"l 11- HONORARY FELLOW'S ADDRESS TO IFST 20TH ANNIVERSARY SYMPOSIUM - 16 OCT. 1985 MANCHESTER, ENGLAND IDRC - 1-lb BIOTECHNOLOGY PAST, PRESENT AND POTENTIAL BY: JOSEPH H. HULSE* BIOTECHNOLOGY: ANCIENT AND MODERN Louis Pasteur wrote "There are no applied sciences; there are only applications of science...The study of the application of science is very easy to anyone who is master of the theory". A few years later Lord Kelvin instructed us that "If you can measure that of which you speak, and can express it by a number, you know something of your subject. But if you cannot measure it, your knowledge is meagre and unsatisfactory." It would indeed be interesting to know what the spirits of these distinguished scientists are thinkinq about "Biotechnology" which takes within its broad embrace remarkable new knowledge in cell and molecular biology; some very ancient technologies; together with a large swatch of enpirical observations and discoveries, many of which remain far distant from viable technological application. Fermentation technologies have a very long history: beer, wine, bread and cheese having been around as long as cereals and vine fruits have been harvested and animais have been milked. Homer described wine as a qift from the Gods and Ecclesiasticus wisely advised that "From the beginning wine was created to make men joyful, not to make them drunk." Though ethanolic fermentations have been most pervasive, lactic and other acidic fermentations have appeared in greater diversity, particularly in traditional domestic processes of preservation. The ancient Sumerians 7,000 years ago converted all their milk into cheese in the stated belief that had God intended mankind to have clean milk to drink he would have placed the udders at the front end of the cow.
    [Show full text]
  • Bioelectronics & Nanotechnology
    Bioelectronics & Nanotechnology A Master Degree in Biomedical Sciences – two years – full-time/part-time This unique master degree programme focuses on a novel and interdisciplinary scientific domain at the boundaries between physics, chemistry, electro- nics, and biomedical sciences. Fifty years ago, shortly after J. Watson and F. Crick successfully solved the structure of DNA using X-ray diffraction, R. Feynman made his visionary statement: “There’s plenty of room at the bottom”, with which he effectively heralded the new era of nanosciences. Since that time, research into “functi- onal” molecules and nanomaterials has developed into one of the most important scientific disciplines of today. This is triggered by the fact that a broad range of nanoscopic techniques has become available to study molecules directly at their own length scale and to understand their complex properties. The master programme offers a strong foundation in all fundamental scientific aspects and provides, in addition, an in depth introduction into several important application areas. Topics range from integrated detection and characterization techniques for molecules (biosensors) to the nanoscale engi- neering of implant materials, and the working principles of medical devices like neurochips and pacemakers. The curriculum of this programme was jointly developed by physicists, chemists, clinical and biomedical researchers, and engineers specialized in medi- cal instrumentation. The programme ensures therefore a broad overview of the domain of bioelectronics and nanotechnology and enables the graduates to develop their individual skills for a successful career in interdisciplinary research- and development environments. What are your career prospects ? Educational Concept • Applied and fundamental research at universities, hospitals, and research In view of the international profile of this degree programme, English langu- centers.
    [Show full text]
  • Science & Technology Trends 2020-2040
    Science & Technology Trends 2020-2040 Exploring the S&T Edge NATO Science & Technology Organization DISCLAIMER The research and analysis underlying this report and its conclusions were conducted by the NATO S&T Organization (STO) drawing upon the support of the Alliance’s defence S&T community, NATO Allied Command Transformation (ACT) and the NATO Communications and Information Agency (NCIA). This report does not represent the official opinion or position of NATO or individual governments, but provides considered advice to NATO and Nations’ leadership on significant S&T issues. D.F. Reding J. Eaton NATO Science & Technology Organization Office of the Chief Scientist NATO Headquarters B-1110 Brussels Belgium http:\www.sto.nato.int Distributed free of charge for informational purposes; hard copies may be obtained on request, subject to availability from the NATO Office of the Chief Scientist. The sale and reproduction of this report for commercial purposes is prohibited. Extracts may be used for bona fide educational and informational purposes subject to attribution to the NATO S&T Organization. Unless otherwise credited all non-original graphics are used under Creative Commons licensing (for original sources see https://commons.wikimedia.org and https://www.pxfuel.com/). All icon-based graphics are derived from Microsoft® Office and are used royalty-free. Copyright © NATO Science & Technology Organization, 2020 First published, March 2020 Foreword As the world Science & Tech- changes, so does nology Trends: our Alliance. 2020-2040 pro- NATO adapts. vides an assess- We continue to ment of the im- work together as pact of S&T ad- a community of vances over the like-minded na- next 20 years tions, seeking to on the Alliance.
    [Show full text]
  • Biosensing and Bioelectronics
    Rutgers University Electrical and Computer Engineering Department ECE 493/599 Biosensors and Bioelectronics Index Number 16320 Date: Fall 2015 Credits: 3 Time: TBA Location CORE 538 Grading 20% HW, 40% Midterm Exams, 10% Paper Presentation, 30% Final Project Final Exam None Instructor Mehdi Javanmard, PhD. Course TA: TBA Textbook: Kirby, Micro- and Nanoscale Fluid Mechanics (2010) Class slides will be available on the class website. Prerequisites: 14:332:361 Electronic Devices Further Reading: Saliterman, Fundamentals of BioMEMS and Medical Microdevices (2009) Stryer, Lubert Biochemistry 5th Edition (2008) Description of Course: The course covers state-of-the-art and emerging biosensors, biochips, microfluidics, which will be studied in the context of molecular diagnostics. Students will briefly learn the relevant biology, biochemistry, and molecular biology pertinent to molecular diagnostics and cancer. Students will also become equipped with a thorough understanding of the interfaces between electronics, optics, molecular biology, and cancer biology for engineers. Topics will include microfluidics and mass transfer limits, electrode-electrolyte interfaces, electrochemical noise processes, biosensor system level characterization, determination of performance parameters such as throughput, detection limit, and cost, integration of sensor with microfluidics, and electronic readout circuitry architectures Novel nanobiosensors such as nanopores, nanowire FETS, surface plasmon resonance, surface enhanced Raman scattering, fluorescence and single molecule detection will also be covered. Emphasis will be placed on hands-on in-depth quantitative design of biomolecular sensing platforms. Course intent 1. To introduce the major biochemical and molecular processes relevant in molecular diagnostics. 2. To introduce the major molecular processes relevant to cancer. 3.To introduce and provide an understanding of emerging micro- and nanotechnologies for biomarker based disease diagnosis.
    [Show full text]
  • Overview on the Detection, Interpretation and Reporting on the Presence of Unauthorised Genetically Modified Materials
    Overview on the detection, interpretation and reporting on the presence of unauthorised genetically modified materials Guidance document from the European Network of GMO Laboratories (ENGL) ENGL ad hoc working group on “unauthorised GMOs” EUR 25008 EN - 2011 The mission of the JRC-IHCP is to protect the interests and health of the consumer in the framework of EU legislation on chemicals, food, and consumer products by providing scientific and technical support including risk-benefit assessment and analysis of traceability. European Commission Joint Research Centre Institute for Health and Consumer Protection Contact information Address: Molecular Biology and Genomics Unit E-mail: [email protected] Tel.: +39 0332 789379 Fax: +39 0332 786159 http://ihcp.jrc.ec.europa.eu/ http://www.jrc.ec.europa.eu/ Legal Notice Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of this publication. Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server http://europa.eu/ JRC 67297 EUR 25008 EN ISBN 978-92-79-21800-2 ISSN 1831-9424 doi: 10.2788/89665 Luxembourg: Publications Office of the European Union © European Union, 2011 Reproduction is authorised provided
    [Show full text]
  • Detection and Traceability of Genetically Modified Organisms In
    Food and Chemical Toxicology 42 (2004) 1157–1180 www.elsevier.com/locate/foodchemtox Detection and traceability of genetically modified organisms in the food production chain M. Miragliaa,*, K.G. Berdalb, C. Breraa, P. Corbisierc, A. Holst-Jensenb, E.J. Kokd, H.J.P. Marvind, H. Schimmelc, J. Rentsche, J.P.P.F. van Ried, J. Zagonf aIstituto Superiore di Sanita´, Section of Cereal Chemistry, Laboratory of Food, Viale Regina Elena 299, I-00161 Rome, Italy bNational Veterinary Institute, Section of Food and Feed Microbiology, Ullevaalsveien 68, N-0033 Oslo, Norway cEuropean Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Reference Materials Unit, Retieseweg, B-2440 Geel, Belgium dRIKILT-Institute of Food Safety, Wageningen University & Research Centre, Bornsesteeg 45, PO Box 230, NL-6700AE Wageningen, The Netherlands eMolecular Biology Unit, Swiss Quality Testing Services, Rte. de l’Industrie 61, CH-1784 Courtepin, Switzerland fCentre for Novel Foods and Genetic Engineering, Federal Institute for Risk Assessment, Thielallee 88-92, D-14195 Berlin, Germany Received 16 November 2003; accepted 4 February 2004 Abstract Both labelling and traceability of genetically modified organisms are current issues that are considered in trade and regulation. Currently, labelling of genetically modified foods containing detectable transgenic material is required by EU legislation. A pro- posed package of legislation would extend this labelling to foods without any traces of transgenics. These new legislations would also impose labelling and a traceability system based on documentation throughout the food and feed manufacture system. The regulatory issues of risk analysis and labelling are currently harmonised by Codex Alimentarius. The implementation and main- tenance of the regulations necessitates sampling protocols and analytical methodologies that allow for accurate determination of the content of genetically modified organisms within a food and feed sample.
    [Show full text]
  • NIST's Perspective on Bioelectronics
    November 4, 2008 David G. Seiler, Chief Semiconductor Electronics Division Electronics and Electrical Engineering Laboratory SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 1 NIST ◦ Innovation ◦ Bioscience and Health Bioelectronics: A New Frontier Summary SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 2 From E. Steel, “The Innovation Ecosystem,” June 2008. SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 3 From E. Steel, “The Innovation Ecosystem,” June 2008. SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 4 Biotechnology Bioscience and Health Is Identified as an Area for Significant Growth at NIST Adapted from W. May, “Overview of Partnerships with The Hollings Marine Laboratory and The University of Maryland Biotechnology Institute,” June 10, 2008. SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 5 It is congruent with our mission, and indeed our mandate, to support U.S. industry and other stakeholders in overcoming measurement and standards-related challenges in the biosciences by leveraging our vast multidisciplinary expertise in the quantitative physical and informational sciences, to: . provide the measurement infrastructure to provide confidence in the results from measurements of complex biological systems Which will . enable and facilitate realization of optimal economic and broad societal benefits from new innovations SRC & NIST Bioelectronics Roundtable, Nov. 4, 2008 6 • FY07 Budget Increase Calibration and IT standards for MRI, CT, PET and cellular imaging • FY09 Budget Request Technology and standards for
    [Show full text]
  • Biosensors and Bioelectronics Bioelectrochemical Systems
    Biosensors and Bioelectronics 142 (2019) 111576 Contents lists available at ScienceDirect Biosensors and Bioelectronics journal homepage: www.elsevier.com/locate/bios Bioelectrochemical systems: Sustainable bio-energy powerhouses T ∗ Mahwash Mahar Gul, Khuram Shahzad Ahmad Department of Environmental Sciences, Fatima Jinnah Women University, The Mall, Rawalpindi, 46000, Pakistan ARTICLE INFO ABSTRACT Keywords: Bioelectrochemical systems comprise of several types of cells, from basic microbial fuel cells (MFC) to photo- Microbial fuel cells synthetic MFCs and from plant MFCs to biophotovoltaics. All these cells employ bio entities at anode to produce Photo MFCs bioenergy by catalysing organic substrates while some systems convert solar irradiation to energy. The current Plant MFCs review epitomizes the above-mentioned fuel cell systems and elucidates their electrical performances. Microbial Biophotovoltaics fuel cells have advantages over conventional fuel cells in terms of being sustainable whilst producing impressive Bioelectricity power efficiencies without any net carbon emissions. They can be utilized for several environmentally friendly applications including wastewater treatment and bio-hydrogen generation, apart from producing clean and green electricity. Multifarious heterotrophic and autotrophic microbes and plants have been studied for their potential as imperative components of fuel cell technology. MFCs also display some interesting applications, such as integration of plant MFCs into architecture to produce “green” cities. Biophotovoltaic technology is the current hot cake in this field, which aspires to achieve significant electrical efficiencies by light-induced water splitting mechanisms. Furthermore, the utilization of BPVs in space renders it a technology for the future. Compared with other fuel cell systems, this technology is still in its inception and requires further efforts to endeavour its use on commercial or industrial level.
    [Show full text]